Iovance Biotherapeutics (NASDAQ:IOVA – Free Report) had its price target raised by Citizens Jmp from $5.00 to $8.00 in a report published on Friday morning,Benzinga reports. Citizens Jmp currently has a market outperform rating on the biotechnology company’s stock.
Other equities research analysts have also recently issued reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Iovance Biotherapeutics in a report on Thursday, July 2nd. Citigroup reiterated an “outperform” rating on shares of Iovance Biotherapeutics in a research note on Friday. Chardan Capital cut their price objective on Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Barclays increased their target price on Iovance Biotherapeutics from $11.00 to $13.00 and gave the company an “overweight” rating in a research note on Friday. Finally, Robert W. Baird set a $6.00 price target on Iovance Biotherapeutics in a research report on Friday. Five analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $8.00.
Read Our Latest Research Report on Iovance Biotherapeutics
Iovance Biotherapeutics Trading Up 2.1%
Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) last posted its earnings results on Thursday, August 6th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. The business had revenue of $198.63 million for the quarter, compared to analyst estimates of $87.83 million. Iovance Biotherapeutics had a negative net margin of 89.11% and a negative return on equity of 40.92%. Iovance Biotherapeutics’s revenue was up 65.7% compared to the same quarter last year. During the same period last year, the business posted ($0.33) EPS. As a group, research analysts predict that Iovance Biotherapeutics will post -0.6 earnings per share for the current year.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the stock. Aberdeen Group plc increased its stake in Iovance Biotherapeutics by 25.1% during the fourth quarter. Aberdeen Group plc now owns 759,522 shares of the biotechnology company’s stock valued at $2,073,000 after acquiring an additional 152,312 shares during the period. Knott David M Jr bought a new stake in shares of Iovance Biotherapeutics in the 1st quarter worth approximately $5,616,000. Vanguard Group Inc. lifted its position in shares of Iovance Biotherapeutics by 13.1% in the 4th quarter. Vanguard Group Inc. now owns 27,207,079 shares of the biotechnology company’s stock worth $74,275,000 after acquiring an additional 3,148,096 shares during the period. Profund Advisors LLC grew its holdings in shares of Iovance Biotherapeutics by 149.7% during the 4th quarter. Profund Advisors LLC now owns 260,660 shares of the biotechnology company’s stock worth $712,000 after purchasing an additional 156,253 shares in the last quarter. Finally, Leonteq Securities AG acquired a new stake in shares of Iovance Biotherapeutics during the 4th quarter worth approximately $532,000. Institutional investors and hedge funds own 77.03% of the company’s stock.
Iovance Biotherapeutics News Roundup
Here are the key news stories impacting Iovance Biotherapeutics this week:
- Positive Sentiment: Record revenue and strong Amtagvi demand: Second-quarter revenue reached approximately $99.3 million, up 66% year over year and well above analyst expectations. U.S. Amtagvi revenue was about $91 million, rising 40% from the fourth quarter, helping drive the earnings beat. Iovance Q2 2026 results
- Positive Sentiment: Loss narrowed and margins improved: Iovance reported a loss of $0.11 per share, better than the $0.13–$0.17 consensus range and an improvement from $0.33 per share a year earlier. Gross margin increased to 56% as manufacturing and cost efficiencies improved. Zacks Q2 earnings report
- Positive Sentiment: Analyst support strengthened: Citizens JMP raised its IOVA price target from $5 to $8 and assigned a “market outperform” rating, reinforcing bullish sentiment following the results. Benzinga analyst update
- Positive Sentiment: Pipeline catalysts expanded: The FDA granted Fast Track Designation to lifileucel for soft tissue sarcomas. Investors are also focused on upcoming data from melanoma and non-small-cell lung cancer programs, with additional trial updates expected later this year. Iovance pipeline update
- Neutral Sentiment: Management is reviewing its 2026 revenue outlook of $350 million to $370 million because of stronger demand, but plans to provide an updated forecast in the third quarter. The company ended June with approximately $304 million in cash, expected to fund operations into the second half of 2028.
- Negative Sentiment: Iovance remains unprofitable, posting a quarterly net loss of approximately $47.3 million, while research and development expenses totaled $58.9 million. Continued losses and execution risks around commercialization and clinical trials remain important risks for investors.
Iovance Biotherapeutics Company Profile
Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.
Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.
Featured Articles
- Five stocks we like better than Iovance Biotherapeutics
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
